Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 3/20 | 0.53 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.47 |
| ▸ | ADA | P00813 | 1/20 | 0.47 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.47 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.47 |
| ▸ | SLC29A1 | Q99808 | 6/20 | 0.44 |
| ▸ | NT5E | P21589 | 2/20 | 0.44 |
| ▸ | PGK1 | P00558 | 1/20 | 0.43 |
| ▸ | PGK2 | P07205 | 1/20 | 0.43 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.43 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1552038 | 1.00 | ADORA2A (0.53) | ADORA2ACYP2C19ADAADORA3ADORA1 | |
| SCHEMBL15038015 | 0.90 | ADORA2A (0.62) | ADORA2ACYP2C19ADAADORA3ADORA1 | |
| SCHEMBL18061789 | 0.90 | ADORA2A (0.62) | ADORA2ACYP2C19ADAADORA3ADORA1 | |
| SCHEMBL20991001 | 0.90 | ADORA2A (0.62) | ADORA2ACYP2C19ADAADORA3ADORA1 | |
| SCHEMBL12849772 | 0.90 | ADORA2A (0.62) | ADORA2ACYP2C19ADAADORA3ADORA1 | |
| SCHEMBL465590 | 0.90 | ADORA2A (0.62) | ADORA2ACYP2C19ADAADORA3ADORA1 | |
| SCHEMBL465589 | 0.90 | ADORA2A (0.62) | ADORA2ACYP2C19ADAADORA3ADORA1 | |
| SCHEMBL13929038 | 0.90 | ADORA2A (0.62) | ADORA2ACYP2C19ADAADORA3ADORA1 | |
| SCHEMBL13066843 | 0.89 | ADORA2A (0.53) | ADORA2ACYP2C19ADAADORA3ADORA1 | |
| SCHEMBL12202863 | 0.89 | ADORA2A (0.53) | ADORA2ACYP2C19ADAADORA3ADORA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2313422-B1 | NUCLEOSIDE CYCLICPHOSPHATES | GILEAD PHARMASSET LLC (US) | 2015-03-04 | — | — | EP | disclosed |
| US-8759510-B2 | Nucleoside cyclicphosphates | GILEAD PHARMASSET LLC (US) | 2014-06-24 | — | — | US | disclosed |
| US-20120258928-A1 | NUCLEOSIDE CYCLICPHOSPHATES | GILEAD PHARMASSET LLC (US) | 2012-10-11 | — | — | US | disclosed |
| US-8173621-B2 | Nucleoside cyclicphosphates | GILEAD PHARMASSET LLC (US) | 2012-05-08 | — | — | US | disclosed |
| EP-2313422-A2 | NUCLEOSIDE CYCLICPHOSPHATES | Pharmasset, Inc. (US) | 2011-04-27 | — | — | EP | disclosed |
| US-20100081628-A1 | NUCLEOSIDE CYCLICPHOSPHATES | PHARMASSET, INC. (US) | 2010-04-01 | — | — | US | disclosed |
| WO-2009152095-A2 | NUCLEOSIDE CYCLICPHOSPHATES | PHARMASSET, INC. (US) | 2009-12-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120258928-A1 | NUCLEOSIDE CYCLICPHOSPHATES | PNP, NUDT1, TYMP | ADORA2A 102/4885CYP2C19 2793/4885ADA 22/4885 |
| US-20100081628-A1 | NUCLEOSIDE CYCLICPHOSPHATES | PNP, NUDT1, TYMP | ADORA2A 102/4885CYP2C19 2793/4885ADA 22/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.